Claims for Patent: 7,387,793

Summary for Patent: 7,387,793

Title:	Modified release dosage forms of skeletal muscle relaxants
Abstract:	A unit dosage form, such as a capsule or the like, for delivering a skeletal muscle relaxant, such as cyclobenzaprine hydrochloride, into the body in an extended or sustained release fashion comprising one or more populations of drug-containing particles (beads, pellets, granules, etc.) is disclosed. At least one bead population exhibits a pre-designed sustained release profile. Such a drug delivery system is designed for once-daily oral administration to maintain an adequate plasma concentration--time profile, thereby providing relief of muscle spasm associated with painful musculoskeletal conditions over a 24 hour period.
Inventor(s):	Venkatesh; Gopi (Vandalia, OH), Clevenger; James M. (Vandalia, OH)
Assignee:	Eurand, Inc. (Vandalia, OH)
Application Number:	10/713,929
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 7,387,793
Patent Claims:	1. A multi-particulate pharmaceutical dosage form of a skeletal muscle relaxant providing a modified release profile comprising a population of extended release beads, wherein said extended release beads comprise an active-containing core particle comprising a skeletal muscle relaxant selected from the group consisting of cyclobenzaprine, pharmaceutically acceptable salts or derivatives thereof and mixtures thereof; and an extended release coating comprising a water insoluble polymer membrane surrounding said core, wherein said dosage form when dissolution tested using United States Pharmacopoeia Apparatus 2 (paddles @ 50 rpm) in 900 mL of 0.1N HCl at 37.degree. C. exhibits a drug release profile substantially corresponding to the following pattern: after 2 hours, no more than about 40% of the total active is released; after 4 hours, from about 40-65% of the total active is released after 8 hours, from about 60-85% of the total active is released; wherein said dosage form provides therapeutically effective plasma concentration over a period of 24 hours to treat muscle spasm associated with painful musculoskeletal conditions when administered to a patient in need thereof; and wherein said water insoluble polymer membrane comprises a water insoluble polymer selected from the group consisting of ethers of cellulose, esters of cellulose, cellulose acetate, ethyl cellulose, polyvinyl acetate, neutral copolymers based on ethylacrylate and methylmethacrylate, copolymers of acrylic and methacrylic acid esters with quaternary ammonium groups, pH-insensitive ammonio methacrylic acid copolymers, and mixtures thereof; and a plasticizer selected from the group consisting of triacetin, tributyl citrate, tri-ethyl citrate, acetyl tri-n-butyl citrate, diethyl phthalate, dibutyl sebacate, polyethylene glycol, polypropylene glycol, castor oil, acetylated mono- and di-glycerides and mixtures thereof. 2. The pharmaceutical dosage form of claim 1, wherein said skeletal muscle relaxant comprises cyclobenzaprine hydrochloride. 3. The pharmaceutical dosage form of claim 2 wherein said pharmaceutical dosage form provides a maximum blood plasma concentration (C.sub.max) within the range of about 80% to 125% of about 20 ng/mL of cyclobenzapnine HCl and an AUC.sub.0-168 within the range of about 80% to 125% of about 740 nghr/mL and a T.sub.max within the range of 80% to 125% of about 7 hours following oral administration of a single 30 mg cyclobenzapnine HCl MR Capsule. 4. The pharmaceutical dosage form of claim 3 wherein the adjusted mean ratio of CMR 30 mg/CMR 15 mg is greater than about 2 for each of AUC.sub.0-168 (p<0.001), AUC.sub.0-.infin. (p<0.001), and C.sub.max (p<0.001). 5. The pharmaceutical dosage form of claim 1, wherein said dosage form comprises only one extended release bead population. 6. The pharmaceutical dosage form of claim 1, wherein said water insoluble polymer membrane on the drug cores comprises from about 7% to 12% by weight of the extended release beads. 7. The pharmaceutical dosage form of claim 1, wherein said extended release coating further comprises a water soluble polymer selected from the group consisting of methylcellulose, hydroxypropylcellulose, hydroxypropyl methylcellulose, polyethylene glycol polyvinylpyrrolidone and mixtures thereof. 8. The pharmaceutical dosage form of claim 1, wherein said skeletal muscle relaxant comprises cyclobeuzaprine. 9. The pharmaceutical dosage form of claim 1, wherein said drug release profile substantially corresponds to the following pattern: after 2 hours, no more than about 40% of the total active is released; after 4 hours, from about 40-65% of the total active is released; after 8 hours, from about 60-85% of the total active is released; and after 12 hours, from about 75-85% of the total active is released. 10. The pharmaceutical dosage form of claim 1, wherein said extended release coating further comprises a water soluble polymer selected from the group consisting of methylcellulose, hydroxypropylcellulose, hydroxypropyl methylcellulose, polyethylene glycol polyvinylpyrrolidone and mixtures thereof. 11. The pharmaceutical dosage form of claim 1, wherein the water insoluble polymer membrane comprises ethyl cellulose. 12. The pharmaceutical dosage form of claim 11, wherein said plasticizer is diethyl phthalate. 13. The pharmaceutical dosage form of claim 11, wherein the extended release coating further comprises a water soluble polymer selected from the group consisting of methylcellulose, hydroxypropylcellulose, hydroxypropyl methylcellulose, polyethylene glycol polyvinylpyrrolidone and mixtures thereof. 14. The pharmaceutical dosage form of claim 12, wherein the extended release coating further comprises a water soluble polymer selected from the group consisting of methylcellulose, hydroxypropylcellulose, hydroxypropyl methylcellulose, polyethylene glycol polyvinylpyrrolidone and mixtures thereof. 15. The pharmaceutical dosage form of claim 14, wherein the water soluble polymer is hydroxypropyl methylcellulose. 16. The pharmaceutical dosage form of claim 15, wherein the skeletal muscle relaxant is cyclobenzaprine hydrochloride. 17. The pharmaceutical dosage form of claim 16, wherein the water insoluble polymer membrane comprises from about 7% to 12% by weight of the extended release beads. 18. The pharmaceutical dosage form of claim 17, wherein the drug release profile substantially corresponds to the following pattern: after 2 hours, no more than about 40% of the total active is released; after 4 hours, from about 40-65% of the total active is released; after 8 hours, from about 60-85% of the total active is released; and after 12 hours, from about 75-85% of the total active is released. 19. The pharmaceutical dosage form of claim 1, wherein said water insoluble polymer membrane comprises a water insoluble polymer selected from the group consisting of ethers of cellulose, esters of cellulose, pH-insensitive ammonio methacrylic acid copolymers, and mixtures thereof. 20. The pharmaceutical dosage form of claim 19, wherein said extended release coating further comprises a water soluble polymer selected from the group consisting of methylcellulose, hydroxypropylcellulose, hydroxypropyl methylcellulose, polyethylene glycol polyvinylpyrrolidone and mixtures thereof.